£810 / $1295 / €985
Malaysia ' s healthcare sector is showing strong signs of growth, with increased internal and investment in pharmaceutical manufacturing facilities in a move to boost exports. Key growth areas include biotechnology; namely drug discovery, new product development , technology acquisition and licensing ; generic drug production; and the recent release of h alal pharmaceutical guidelines mean s Malaysia has the potential to take a le ading role in the fast-growing h alal pharmaceutical market. While concerns remain regarding intellectual property - Malaysia has presented objections to elements in the Trans-Pacific Partnership Agreement - it is making progress in terms of trade relations: the government began negotiations over the creation of a European Free Trade Agreement in November 2012. Malaysia suffers a burden of both communicable and non-communicable diseases, with diabetes a growing concern for pol icymakers: the government forecasts there will be 4.5mn sufferers of the disease by 2020, compared to 2.6mn in 2011.
Headline Expenditure Projections
Pharmaceuticals: MYR5.55bn (US$1.81bn) in 2011 to MYR6.1bn (US$1.93bn) in 2012; +10.2% in local currency and +6.2% in US dollars. Forecast unchanged from Q4 12.
Healthcare: MYR36.35bn (US$11.88bn) in 2011 to MYR38.85bn (US$12.24bn) in 2012; +6.9% in local currency and +3.0% in US dollars. Forecast lowered from Q4 12 on account of macroeconomic factors.
Medical devices: MYR3.97bn (US$1.30bn) in 2011 to MYR4.29bn (US$1.35bn) in 2012; +8.2% in local currency and +4.3% in US dollars. Forecast lowered from Q4 12 on account of new historical data.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.